**1. Introduction**

438 Non-Viral Gene Therapy

Saranya, N.; Moorthi, A.; Saravanan, S.; Devi, M. P. & Selvamurugan, N. (2011). Chitosan

Stayton, P. S.; El-Sayed, M. E.; Murthy, N.; Bulmus, V.; Lackey, C.; Cheung, C. & Hoffman,

*Craniofacial Research,* Vol. 8, No. 3, (Aug 2005), pp. 219-225, ISSN 1601-6335 Sun, S.; Liu, W.; Cheng, N.; Zhang, B.; Cao, Z.; Yao, K.; Liang, D.; Zuo, A.; Guo, G. & Zhang,

Thanou, M.; Florea, B. I.; Geldof, M.; Junginger, H. E. & Borchard, G. (2002). Quaternized

Uekama, K.; Hirayama, F. & Irie, T. (1998). Cyclodextrin Drug Carrier Systems. *Chemical* 

Wong, K.; Sun, G.; Zhang, X.; Dai, H.; Liu, Y.; He, C. & Leong, K. W. (2006). PEI-g-chitosan, a

Yang, C.; Li, H.; Goh, S. H. & Li, J. (2007). Cationic star polymers consisting of alpha-

Zhao, Q.; Temsamani, J. & Agrawal, S. (1995). Use of cyclodextrin and its derivatives as

Zheng, Y.; Cai, Z.; Song, X.; Yu, B.; Bi, Y.; Chen, Q.; Zhao, D.; Xu, J. & Hou, S. (2009).

Zidovetzki, R. & Levitan, I. (2007). Use of cyclodextrins to manipulate plasma membrane

*Biophysica Acta,* Vol. 1768, No. 6, (Jun 2007), pp. 1311-1324, ISSN 0006-3002 Zugates, G. T.; Anderson, D. G.; Little, S. R.; Lawhorn, I. E. & Langer, R. (2006). Synthesis of

*Biomaterials,* Vol. 23, No. 1, (Jan 2002), pp. 153-159, ISSN 0142-9612

*Reviews,* Vol. 98, No. 5, (Jul 30 1998), pp. 2045-2076, ISSN 1520-6890

*Chemistry,* Vol. 17, No. 1, (Jan-Feb 2006), pp. 152-158, ISSN 1043-1802 Wu, C. H. & Wu, G. Y. (1998). Receptor-mediated delivery of foreign genes to hepatocytes.

*Biomaterials,* Vol. 28, No. 21, (Jul 2007), pp. 3245-3254, ISSN 0142-9612 Zhang, H.; Mardyani, S.; Chan, W. C. & Kumacheva, E. (2006). Design of biocompatible

3, (Fall 1995), pp. 185-192, ISSN 1050-5261

*Macromolecules,* Vol. 48, No. 2, (Mar 1 2011), pp. 234-238, ISSN 1879-0003 Smith, A. E. (1995). Viral vectors in gene therapy. *Annual Review of Microbiology,* Vol. 49,

1995), pp. 807-838, ISSN 0066-4227

980, ISSN 1043-1802

8294

7797

269, ISSN 1873-3476

0002-7863

and its derivatives for gene delivery. *International Journal of Biological* 

A. S. (2005). 'Smart' delivery systems for biomolecular therapeutics. *Orthodontics &* 

J. (2005). A thermoresponsive chitosan-NIPAAm/vinyl laurate copolymer vector for gene transfection. *Bioconjugate Chemistry,* Vol. 16, No. 4, (Jul-Aug 2005), pp. 972-

chitosan oligomers as novel gene delivery vectors in epithelial cell lines.

novel gene delivery system with transfection efficiency comparable to polyethylenimine in vitro and after liver administration in vivo. *Bioconjugate* 

*Advanced Drug Delivery Reviews,* Vol. 29, No. 3, (Feb 2 1998), pp. 243-248, ISSN 1872-

cyclodextrin core and oligoethylenimine arms as nonviral gene delivery vectors.

chitosan microgels for targeted pH-mediated intracellular release of cancer therapeutics. *Biomacromolecules,* Vol. 7, No. 5, (May 2006), pp. 1568-1572, ISSN 1525-

carriers for oligonucleotide delivery. *Antisense Research and Development,* Vol. 5, No.

Receptor mediated gene delivery by folate conjugated N-trimethyl chitosan in vitro. *International Journal of Pharmaceutics,* Vol. 382, No. 1-2, (Dec 1 2009), pp. 262-

cholesterol content: evidence, misconceptions and control strategies. *Biochimica et* 

poly(beta-amino ester)s with thiol-reactive side chains for DNA delivery. *Journal of the American Chemical Society,* Vol. 128, No. 39, (Oct 4 2006), pp. 12726-12734, ISSN In gene therapy, the most important step is how to effectively deliver the therapeutic gene to the target cells or organ. At present, there are two methods, which are those using a viral and a non-viral vector system. The most common viral vectors that have been used include retroviruses, herpes simplex viruses, lentiviruses, adenoviruses and adenoassociated viruses (Oligino et al., 2000). The advantages of most viral vectors are high transfection efficiency and fast transcription of the foreign material inserted in the viral genome. However, a number of disadvantages have also been described, such as poor target-specificity, low capacity to incorporate foreign deoxyribonucleic acid (DNA) sequence to their genome (Mansouri et al., 2004), toxic and inflammatory effects, wild– type mutations, potential oncogenic effects (Lee et al., 1998), and, in particular, unwanted immune responses. In clinical trials of gene replacement therapy using viral vectors, significant adverse effects have been reported, including a fatal inflammatory response associated with adenoviral vector (Raper et al., 2003), and the development of acute leukaemia in recipients of ex-vivo, adenoviral vector-transduced hematopoietic cells (Woods et al., 2006). Intravenous adenoviral vector has also resulted in high liver toxicity due to uptake by hepatocytes or Kupffer cells of the liver reticular endothelial system, immediately following systemic administration.
